Patents by Inventor Kenneth Albert Brameld

Kenneth Albert Brameld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200277312
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 14, 2018
    Publication date: September 3, 2020
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Patent number: 10654843
    Abstract: The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 19, 2020
    Assignee: Principia Biopharma Inc.
    Inventors: Timothy Owens, Kenneth Albert Brameld
  • Patent number: 10538517
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: January 21, 2020
    Assignee: Principia Biopharma, Inc.
    Inventors: Kenneth Albert Brameld, Erik Verner
  • Publication number: 20190336515
    Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: January 16, 2018
    Publication date: November 7, 2019
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Publication number: 20190233418
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 1, 2019
    Inventors: Erik VERNER, Kenneth Albert BRAMELD
  • Patent number: 10294223
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: May 21, 2019
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Publication number: 20180208589
    Abstract: The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: June 18, 2015
    Publication date: July 26, 2018
    Inventors: Timothy Owens, Kenneth Albert Brameld
  • Publication number: 20180155340
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 18, 2016
    Publication date: June 7, 2018
    Inventors: Kenneth Albert BRAMELD, Erik VERNER
  • Publication number: 20180065960
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 8, 2017
    Publication date: March 8, 2018
    Inventors: Erik VERNER, Kenneth Albert BRAMELD
  • Patent number: 9815834
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: November 14, 2017
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Patent number: 9676778
    Abstract: The present disclosure provides compounds of formula (I) wherein the variables are as defined herein that are JAK3 inhibitors and therefore useful for the treatment of diseases treatable by inhibition of JAK3 such as cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: June 13, 2017
    Assignee: PRINCIPIA BIOPHARMA INC.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld, Tim Owens
  • Patent number: 9630963
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: April 25, 2017
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Kenneth Albert Brameld, Erik Verner
  • Patent number: 9573958
    Abstract: The present disclosure is directed to certain inhibitors of kinases such as ITK, BLK, BMX, BTK, JAK3, TEC, TXK, HER2 (ERBB2), or HER4 (ERBB4), in particular ITK, pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by such kinases.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: February 21, 2017
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Kenneth Albert Brameld, Timothy Owens
  • Patent number: 9567334
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: February 14, 2017
    Assignee: Principia Biopharma, Inc.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Publication number: 20160229849
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 11, 2016
    Inventors: Erik VERNER, Kenneth Albert BRAMELD
  • Publication number: 20160200725
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: March 22, 2016
    Publication date: July 14, 2016
    Inventors: Erik VERNER, Kenneth Albert BRAMELD
  • Patent number: 9376438
    Abstract: The present disclosure provides compounds of Formula (I)and pharmaceutically acceptable salts that are tyrosine kinase inhibitors,in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: June 28, 2016
    Assignee: Principia Biopharma, Inc.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld
  • Publication number: 20160130268
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 7, 2014
    Publication date: May 12, 2016
    Inventors: Kenneth Albert BRAMELD, Erik VERNER
  • Publication number: 20150353557
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 6, 2015
    Publication date: December 10, 2015
    Applicant: Principia Biopharma Inc.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld
  • Patent number: 9187487
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: November 17, 2015
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: David M. Goldstein, Kenneth Albert Brameld, Erik Verner